Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| RenovaCare Inc (CE) | RCAR | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.03 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.03 | 0.03 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.000001 - 0.35 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.03 | USD |
RenovaCare Inc (CE) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.62M | 87.35M | 26.06M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
RenovaCare (CE) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RCAR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.03 | 0.03 | 0.03 | 0.03 | 100 | 0.00 | 0.00% |
| 1 Month | 0.0001 | 0.03 | 0.0001 | 0.0005233 | 1,177 | 0.0299 | 29,900.00% |
| 3 Months | 0.000001 | 0.30005 | 0.000001 | 0.0001717 | 2,698 | 0.03 | 2,999,900.00% |
| 6 Months | 0.0001 | 0.30005 | 0.000001 | 0.0001209 | 2,164 | 0.0299 | 29,900.00% |
| 1 Year | 0.0034 | 0.35 | 0.000001 | 0.009917 | 2,773 | 0.0266 | 782.35% |
| 3 Years | 2.41 | 3.23 | 0.000001 | 0.537722 | 15,293 | -2.38 | -98.76% |
| 5 Years | 1.425 | 4.50 | 0.000001 | 1.65 | 17,495 | -1.40 | -97.89% |
RenovaCare (CE) Description
| RenovaCare, Inc. is a development-stage biotechnology and medical device company focusing on the research, development and commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications. The Company does not have any commercialized products. We are currently developing and testing the CellMist System which is a cell isolation procedure that enzymatically renders stem cells from the patients own skin or other tissues. The resulting stem cell suspension is administered topically with our SkinGun spray device as a cell therapy onto wounds, including burns, to facilitate healing. On May 6, 2021 the Food and Drug Administration gave full-approval of the Company's Investigational Device Exemption (IDE) application to proceed with initial clinical testing of the CellMist System and SkinGun spray device in adult burn patients. The clinical trial protocol is an open-label, single-arm clinical study that is enrolling 14 adult human burn subjects with partial-thickness, second-degree deep thermal burn wounds covering between 10% and 30% total body surface area. The Company may engage up to four (4) U.S. burn centers to conduct the clinical study. Currently, the clinical trial is activated, enrolling and treating patients. The CELLMIST 1 clinical study is expected to reach completion in late 2022. |
